AnaptysBio, Inc. ANAB Drug Supply — Collaborative Arrangement Payment
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept anab:CollaborativeArrangementPayment.
The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about AnaptysBio, Inc.'s drug supply — collaborative arrangement payment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AnaptysBio, Inc.'s drug supply — collaborative arrangement payment?
- AnaptysBio, Inc. (ANAB) reported drug supply — collaborative arrangement payment of $5M in Q1 2026.
- What does drug supply — collaborative arrangement payment mean?
- This metric represents revenue or payments recognized from collaborative arrangements specifically associated with the supply of drug products or clinical materials to partners. It reflects the financial value derived from providing pharmaceutical components or manufacturing support within a strategic partnership framework. Tracking this helps investors assess the monetization of the company's supply chain capabilities and the strength of its collaborative business model.